Please note that this product (marketed as Elocta) was withdrawn from the Community Register of designated orphan medicinal products in October 2015 at the request of the sponsor, at the time of the granting of a marketing authorisation.
On 20 September 2010, orphan designation (EU/3/10/783) was granted by the European Commission to Biogen Idec Limited, United Kingdom, for recombinant fusion protein consisting of human coagulation factor VIII attached to the Fc domain of human IgG1 for the treatment of haemophilia A.
This medicine is now known as efmoroctocog alfa.
EU/3/10/783: Public summary of opinion on orphan designation: Recombinant fusion protein consisting of human coagulation factor VIII attached to the Fc domain of human IgG1 for the treatment of haemophilia A (PDF/175.4 KB)
First published: 18/10/2010
Last updated: 19/01/2016
Recombinant fusion protein consisting of human coagulation factor VIII attached to the Fc domain of human IgG1 (efmoroctocog alfa)
|Disease / condition||
Treatment of haemophilia A
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.